SynthesisMedicine2019

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis.

Lei Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.